Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

7.880 -0.440 (-5.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,423,953
Open 8.340
Bid (Size) 7.800 (5)
Ask (Size) 7.890 (2)
Prev. Close 8.320
Today's Range 7.650 - 8.544
52wk Range 5.900 - 28.18
Shares Outstanding 88,140,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics
Via Benzinga
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga

Performance

YTD
-35.5%
-35.5%
1 Month
+5.1%
+5.1%
3 Month
-17.1%
-17.1%
6 Month
-51.1%
-51.1%
1 Year
-69.4%
-69.4%

More News

Read More
Earnings Scheduled For May 8, 2025
Via Benzinga
A Glimpse of Intellia Therapeutics's Earnings Potential
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
Via Benzinga
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Via Benzinga
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
NTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA
From Pomerantz LLP
Via GlobeNewswire
NTLA Deadline: Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $50K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - NTLA
From Pomerantz LLP
Via GlobeNewswire
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
From Faruqi & Faruqi LLP
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Intellia, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Intellia Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Competitive Analysis In The ATTR-CM Field
Via Talk Markets
Topics Stocks / Equities
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
From Pomerantz LLP
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
From The Rosen Law Firm PA
Via GlobeNewswire
The Future of Healthcare: 10 Predictions For The Next Decade
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA
From Robbins LLP
Via GlobeNewswire

Frequently Asked Questions

Is Intellia Therapeutics, Inc. - Common Stock publicly traded?
Yes, Intellia Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Intellia Therapeutics, Inc. - Common Stock trade on?
Intellia Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Intellia Therapeutics, Inc. - Common Stock?
The ticker symbol for Intellia Therapeutics, Inc. - Common Stock is NTLA on the Nasdaq Stock Market
What is the current price of Intellia Therapeutics, Inc. - Common Stock?
The current price of Intellia Therapeutics, Inc. - Common Stock is 7.880
When was Intellia Therapeutics, Inc. - Common Stock last traded?
The last trade of Intellia Therapeutics, Inc. - Common Stock was at 05/14/25 04:00 PM ET
What is the market capitalization of Intellia Therapeutics, Inc. - Common Stock?
The market capitalization of Intellia Therapeutics, Inc. - Common Stock is 694.55M
How many shares of Intellia Therapeutics, Inc. - Common Stock are outstanding?
Intellia Therapeutics, Inc. - Common Stock has 695M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.